By admin 
The Food and Drug Administration official in charge of reviewing infectious disease products is leaving the agency, according to an email viewed by STAT. Adam Sherwat, the director of the Office of Infectious Diseases (OID) in the FDA’s Center for Drug Evaluation and Research (CDER), told colleagues on Wednesday that his last day at the agency will be April 4. “I have been extremely fortunate to work with and learn from colleagues who are dedicated to improving public health and who are guided by integrity, impartiality, and intellect,” Sherwat wrote in the internal communication. While Sherwat did not respond to immediate requests for comment and the specific reasons for his departure remain undisclosed, his exit marks a significant leadership transition for an office that sits at the center of the nation’s defense against emerging pathogens, the ongoing battle against antimicrobial resistance, and the regulatory oversight of some of the world’s most critical therapeutic categories.
Dr. Adam Sherwat’s tenure at the FDA has been defined by a period of unprecedented intensity for the Office of Infectious Diseases. Having served in various leadership capacities within the agency, including as the deputy director of the OID before ascending to the top role, Sherwat has been a pivotal figure in the federal government’s response to the COVID-19 pandemic. His office was responsible for the rigorous evaluation and eventual approval of primary antiviral treatments, such as Pfizer’s Paxlovid and Merck’s Lagevrio, navigating the complex transition from Emergency Use Authorizations (EUAs) to full New Drug Applications (NDAs). This transition required a delicate balance between the urgent need for public access to life-saving medications and the agency’s "gold standard" requirement for safety and efficacy data.
The Office of Infectious Diseases is one of the most operationally diverse units within the CDER. It oversees several key divisions, including the Division of Anti-Infectives, the Division of Antivirals, and the Division of Transplant and Ophthalmology Products. The scope of this portfolio means that Sherwat’s leadership touched everything from common seasonal influenza treatments to high-stakes therapies for multi-drug resistant "superbugs" and complex medications used to prevent organ rejection in transplant recipients. The departure of a director with such deep institutional knowledge and technical expertise creates a vacuum that the FDA will need to fill quickly, especially as the pharmaceutical industry faces a deepening crisis in the development of new antibiotics.
One of the most pressing issues Sherwat navigated during his time at the helm was the stagnating pipeline for new antimicrobial agents. For decades, infectious disease experts have warned of a "silent pandemic" of antimicrobial resistance (AMR), where bacteria, viruses, fungi, and parasites evolve to resist existing drugs. The OID is the primary regulatory gatekeeper for the new tools needed to fight these threats. However, the economic model for antibiotics is notoriously "broken." Unlike chronic medications for heart disease or oncology drugs that can command high prices and long-term use, antibiotics are used sparingly and for short durations to preserve their effectiveness. This has led many major pharmaceutical companies to exit the space entirely, leaving smaller, often venture-backed biotech firms to lead the way.
Under Sherwat’s guidance, the OID worked to implement regulatory flexibilities designed to incentivize development. This included the use of the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), which allows the FDA to approve certain drugs for a limited population of patients with unmet needs based on smaller clinical trials. Sherwat was a frequent participant in public workshops and industry forums, often discussing how the agency could better support developers while maintaining the rigorous standards necessary to protect public health. His departure comes at a time when the legislative landscape for these drugs is also in flux, with advocates pushing for the passage of the PASTEUR Act, which would create a "subscription-style" payment model for antibiotics to decouple a company’s revenue from the volume of drugs sold.
Beyond the technicalities of drug review, Sherwat’s leadership was characterized by a commitment to the FDA’s core mission of impartiality. In his farewell email, his emphasis on "integrity, impartiality, and intellect" reflects the internal culture he sought to foster during a period when the FDA faced significant political pressure. The COVID-19 era saw the agency thrust into the political spotlight like never before, with debates over vaccine mandates, the speed of drug approvals, and the use of unproven treatments. Throughout this, the OID remained a bastion of data-driven decision-making, often serving as the final arbiter on which treatments were backed by sufficient evidence to warrant clinical use.
The timing of Sherwat’s exit, set for early April, coincides with a broader period of reflection and reorganization within the FDA. Commissioner Robert Califf has been overseeing a series of structural changes aimed at modernizing the agency’s functions, particularly in the wake of the pandemic’s lessons. While Sherwat’s departure appears to be a personal career move rather than a result of these reorganizations, it nonetheless adds to the "brain drain" concerns that often plague high-level government scientific roles. The private sector frequently recruits top FDA talent, offering significantly higher compensation and the opportunity to lead clinical development programs within the pharmaceutical industry. Whether Sherwat is heading to a role in industry, academia, or another public health organization remains to be seen.
The impact on the pharmaceutical industry regarding this leadership change cannot be overstated. For companies with infectious disease products in the pipeline, the director of the OID is a critical figure who sets the tone for "Pre-IND" (Investigational New Drug) meetings and "End-of-Phase 2" consultations. These meetings are where the roadmap for a drug’s approval is drawn, and consistency in leadership is highly valued by investors and drug developers alike. An interim or acting director will likely be appointed following April 4, but the search for a permanent successor will be watched closely by stakeholders across the healthcare spectrum.
The challenges awaiting Sherwat’s successor are formidable. In addition to the AMR crisis, the OID must manage the increasing complexity of clinical trials in the infectious disease space. As more patients gain access to existing treatments, finding "treatment-naive" populations for clinical trials becomes more difficult. Furthermore, the rise of global travel and climate change is expanding the geographic range of tropical diseases and vector-borne illnesses, requiring the FDA to evaluate treatments for diseases that were once considered rare in the United States.
Furthermore, the Office of Infectious Diseases has been at the forefront of exploring "non-traditional" therapies, such as bacteriophages (viruses that kill bacteria) and monoclonal antibodies for infectious prevention. These modalities do not always fit neatly into the traditional regulatory frameworks designed for small-molecule pills. Sherwat was instrumental in helping the agency begin to adapt to these new technologies, ensuring that the OID remained at the cutting edge of science.
As the news of his departure circulates through the halls of the FDA’s White Oak campus and the broader scientific community, colleagues have begun to reflect on his legacy. Sherwat is remembered by many as a "scientist’s scientist"—someone who preferred the nuances of clinical data to the fanfare of public-facing roles. His ability to synthesize complex pharmacological data into actionable public health policy earned him the respect of both his subordinates and the agency’s top brass.
In the coming weeks, the FDA is expected to announce a transition plan. This will likely involve appointing a senior member from within the OID or CDER to serve as the acting director while a national search is conducted. The criteria for the next director will be stringent: they must possess not only the medical and scientific credentials to oversee a vast array of infectious disease products but also the political acumen to navigate the various pressures from Congress, patient advocacy groups, and the pharmaceutical industry.
Ultimately, Adam Sherwat’s departure marks the end of a chapter for the Office of Infectious Diseases—a chapter defined by the greatest public health crisis of the century and a renewed focus on the existential threat of drug-resistant pathogens. As he prepares to leave on April 4, the agency he leaves behind is one that has been tested by fire and remains the most influential regulatory body in the world. The work of the OID will continue, driven by the "integrity, impartiality, and intellect" that Sherwat championed, but his absence will undoubtedly be felt as the agency faces the next generation of infectious threats. The search for his replacement will be a litmus test for the FDA’s priorities in a post-pandemic world, signaling how the agency intends to balance the urgent need for innovation with the timeless necessity of clinical rigor.